DEF: Accendra Health Pivots to Home Care, Boosts Equity Plan
Sentiment:
Proxy Statement
Accendra Health, Inc. announces its strategic transformation to a pure-play home-based care business following the sale of its Products & Healthcare Services segment, alongside proposals for its 2026 Annual Meeting.
Delay expectedThe intended acquisition of Rotech Healthcare Holdings, Inc. was terminated, resulting in a transaction breakage fee and related financing costs.
Worse than expectedThe company underperformed relative to its total-company financial goals for 2025.The 2025 Annual Incentive Plan (AIP) for the total company was funded at 0% of the target performance level.Actual 2025 Total Adjusted EBITDA was $426 million against a target of $575 million.Actual 2025 Total Revenue was $10,665 million against a target of $11,000 million.Actual 2025 Net Debt Reduction was $0 million against a target of $100 million (excluding P&HS sale proceeds).Cumulative adjusted EPS for PSUs granted in 2023 was below the threshold, resulting in the forfeiture of all such PSUs.
Summary
- Completed the sale of the Products & Healthcare Services (P&HS) business and Owens & Minor brand on December 31, 2025, retaining an equity stake.
- Launched Accendra Health as a focused organization dedicated to advancing healthcare in the home, operating through Apria and Byram Healthcare brands.
- Generated total revenue of $10.672 billion, total adjusted operating income of $215 million, total adjusted EBITDA of $424 million, and total adjusted net income per common share of $0.61 for 2025.
- Total debt increased by $209 million, while net debt was reduced by $46 million.
- Used $102 million of operating cash flow, which included the generation of $154 million of operating cash flow from continuing operations.
- Proposes to elect six directors, ratify KPMG LLP as independent auditor, conduct an advisory vote on executive compensation, and approve the Amended and Restated 2023 Omnibus Incentive Plan at the May 14, 2026 Annual Meeting.
- The 2025 Annual Incentive Plan (AIP) for the total company was funded at 0% of target due to underperformance against financial metrics (Adjusted EBITDA, Revenue, Net Debt Reduction).
- The Patient Direct segment achieved 20% of its 2025 AIP target.
- The Executive Deferred Compensation and Retirement Plan (EDCP) was frozen effective January 1, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing with mixed sentiment. While the strategic pivot to home-based care is a positive long-term move aligning with market trends, the immediate financial underperformance in 2025 and the forfeiture of prior PSU awards indicate short-term operational challenges and missed targets.
Positives
- Successful strategic evolution to a pure-play, home-based care business with the sale of the P&HS segment on December 31, 2025.
- Patient Direct segment (now the entirety of Accendra Health) delivered solid financial and operational results in 2025, with revenue growth of 3.1%, adjusted operating income growth of 4.2%, and adjusted EBITDA growth of 1.2% compared to 2024.
- Deployment of 24 new electric vehicles in 2025, expanding the low-emission fleet and supporting sustainable operations.
- Full integration of an idle-time reduction program into fleet operations, contributing to measurable reductions in fuel consumption and carbon output.
- Accendra Health Foundation contributed over $3 million to charitable and civic organizations since its inception, including over $1.5 million for multi-year support of Ronald McDonald House Charities programming.
- Employees volunteered over 200 hours to support over 500 RMHC families in 2025.
- Strong shareholder support for executive compensation in previous years (95% in 2025, 98% in 2024, 97% in 2023).
- The Amended and Restated 2023 Omnibus Incentive Plan includes several shareholder-friendly features such as no automatic award grants, no liberal share recycling, double-trigger change in control provisions, no tax gross-ups, and a clawback policy.
Negatives
- Overall company underperformed relative to total-company financial goals for 2025, leading to a 0% funding of the annual total company bonus pool.
- Total debt increased by $209 million in 2025.
- The intended acquisition of Rotech Healthcare Holdings, Inc. was terminated, resulting in a transaction breakage fee of $80 million and $12 million in net interest paid, plus $6.7 million in deferred debt issuance costs.
- Cumulative adjusted EPS for PSUs granted in 2023 was below the threshold for the three-year period ending December 31, 2025, resulting in the forfeiture of all such PSUs.
- Net loss, as reported (GAAP), was $(1,100,642) thousand for the year ended December 31, 2025.
- Loss from discontinued operations, net of tax, was $997,960 thousand for the year ended December 31, 2025.
- Three of the five Named Executive Officers (NEOs) were not awarded annual bonus payments under the AIP for 2025 due to overall company underperformance.
- NEOs were below their applicable target stock ownership levels as of December 31, 2025, solely due to the then-current price of the company's equity.
Risks
- Increasing competitive and pricing pressures in the marketplace.
- Ability to retain existing and attract new customers and dependence on certain customers, vendors, suppliers, and third-parties.
- Ability to successfully identify, manage, or integrate acquisitions.
- Risks arising from the legal, regulatory, or licensing requirements of the markets in which the company operates.
- General economic, regulatory, and business conditions, including related to international operations.
- Cybersecurity and information security risks, including threats to systems protection.
- Risks associated with compensation programs, though the company states it mitigates these.
Future Outlook
Accendra Health is strengthening its core businesses through investments in technology, automation, and streamlined processes to deliver a simpler and more efficient experience in home-based care. The company anticipates steady growth, strong free cash flow generation, consistent earnings, and continued balance sheet strengthening, aiming to deliver sustainable long-term value for shareholders in the growing market for home-based care.
Management Comments
- "With the sale of the Products & Healthcare Services business and Owens & Minor brand finalized on December 31, 2025, we launched Accendra Health as a more focused organization dedicated to advancing healthcare in the home and beyond. This strategic move allows us to focus our investments and resources on areas with substantial long-term opportunities." Edward A. Pesicka, President & CEO.
- "Aging populations, increasing rates of chronic conditions, and the need for more affordable care options with positive outcomes outside of institutional settings are driving the demand for home-based healthcare. With our scale, expertise, and established relationships across the healthcare ecosystem, we believe Accendra Health is an ideal choice to meet this demand." Edward A. Pesicka, President & CEO.
- "The decision to pursue the divestiture was driven by the recognition that the P&HS business was the lower growth, lower profitability business between our two segments. Although we achieved our strategic objective of divesting that segment, we nevertheless had to absorb the underperformance of the P&HS business for the entirety of 2025." Our People & Culture Committee.
- "Looking forward, the OP&C Committee will evaluate our compensation and governance practices to ensure alignment with our transformed Company, adherence to our overall philosophy, and cognizance of prevailing market dynamics. In so doing we will continue our commitment to ensuring that Accendra Healths executive compensation programs are designed to incentivize business performance and value creation for our shareholders." Our People & Culture Committee.
Industry Context
StockSavvy.ai notes that Accendra Health's strategic pivot to a pure-play home-based care model aligns with significant industry tailwinds, including an aging global population, rising prevalence of chronic conditions, and a growing demand for cost-effective care delivery outside traditional institutional settings. This focus positions Accendra Health to capitalize on a market segment experiencing robust expansion, differentiating it from broader healthcare distributors and aligning with trends seen in specialized home health providers.
Comparison to Industry Standards
- Accendra Health states it is "reasonably aligned with median revenues when compared to the peer group" (2025 peer group included companies like AdaptHealth Corp., Baxter International Inc., Boston Scientific Corporation, Quest Diagnostics Incorporated, ResMed Inc., etc.).
- The company generally targets total compensation packages for Named Executive Officers (NEOs) to reflect the 50th percentile of its peer group when financial and operational goals are achieved.
- The 2026 peer group, adjusted for the strategic shift, includes companies like AdaptHealth Corp., Addus HomeCare Corporation, Amedisys, Option Care Health, Inc., and Select Medical Holdings Corporation, indicating a focus on specialized home care and post-acute services.
- The average burn rate for equity plans for the three years ending December 31, 2025, was 2.38%, and total potential dilution (including proposed new shares) is 12.65%, which the company believes is reasonable for its industry and market conditions.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Executive Vice President and CEO, Products & Healthcare Services | Andrew G. Long | N/A | 2026-01-01 | Left the Company in connection with the divestiture of the P&HS business. |
| Chief Human Resources Officer | N/A (position eliminated/consolidated) | N/A | N/A | Chief Human Resources Officer elected to depart to right-size the executive team and better fit the go-forward strategy of Accendra Health. |
| Executive Vice President and Chief Operating Officer | EVP, CEO of Patient Direct | Perry A. Bernocchi | 2025-12-05 | Transitioned to a new role to streamline the company's leadership model following the P&HS divestiture. |
| Executive Vice President, General Counsel & Corporate Secretary (with added HR oversight) | Executive Vice President, General Counsel & Corporate Secretary | Heath H. Galloway | 2026-01-01 | Assumed oversight responsibility for Accendra Health's human resources function to streamline leadership. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Size Reduction | The Board reduced the number of directors to six following the divestiture of the P&HS business to create a smaller, more nimble Board. | N/A (approved by Board) | Aims to enhance agility and focus in line with the company's new pure-play home-based care strategy. |
| Director Independence | All directors, including the Board Chair, are independent except for the CEO. Only independent directors serve on the Audit, Governance & Nominating, and Our People & Culture Committees. | Ongoing | Ensures strong independent oversight and adherence to best practices in corporate governance. |
| Annual Board and Committee Self-Evaluation | The Board and each of its committees conduct an annual self-evaluation to assess their respective performance. | Ongoing | Promotes continuous improvement and effectiveness of board oversight. |
| Director Age Limit | Bylaws provide that no director nominee can stand for election if over age 72, with temporary waiver possibility under exceptional circumstances. | Ongoing | Aims to maintain a refreshed and relevant board composition, though allows for flexibility. |
| Majority Voting Standard for Directors | Majority voting standard for uncontested director elections (plurality in contested elections), with incumbent directors submitting irrevocable resignations if they fail to receive the required vote. | Ongoing | Enhances shareholder influence in director elections and board accountability. |
| Proxy Access | Shareholders owning 3% or more of stock for at least three years can nominate the greater of two nominees or 20% of board seats for inclusion in proxy materials. | Ongoing | Increases shareholder democracy and ability to influence board composition. |
| Insider Trading Policy | Prohibits hedging or pledging Accendra Health stock by directors, officers, and teammates with confidential information. | Ongoing | Prevents conflicts of interest and promotes alignment of interests with long-term shareholders. |
| Recoupment (Clawback) Policy | Policy for incentive compensation and all time-vesting equity awards in circumstances involving restatement of financial statements, complying with NYSE clawback rules. | Ongoing | Mitigates imprudent risk-taking and ensures accountability for financial misstatements. |
| Stock Ownership Requirements | Substantial stock ownership requirements for directors and executive officers (e.g., CEO 6x base salary, EVP 2x base salary). | Ongoing | Aligns the interests of management and directors with those of long-term shareholders. |
| Virtual Annual Meeting Format | The Annual Meeting of Shareholders will be held virtually via the Internet. | 2026-05-14 | Increases accessibility for shareholders from any geographic location while reducing costs and environmental impact. |
| Amended and Restated 2023 Omnibus Incentive Plan | Shareholders are asked to approve an amendment to increase shares available for issuance by 2,340,000, increase ISO shares by 2,340,000, and remove exceptions to non-employee director compensation limits. | Upon shareholder approval | Aims to maintain flexibility and sufficient share reserve to incentivize talent, while incorporating shareholder-friendly features like minimum vesting terms and no repricing without approval. |
Legal Proceedings
- Litigation and related charges of $2,418 thousand were incurred for the year ended December 31, 2025, primarily for settlement costs and related charges of certain legal matters.
Related Party Transactions
- The Company has not entered any such related party transactions.
Stakeholder Impact
- Shareholders: Direct impact on voting rights for directors, auditor, executive compensation, and incentive plan. Potential for long-term value creation from strategic shift, but short-term financial underperformance and PSU forfeiture may raise concerns.
- Employees (Teammates): Executive compensation programs are designed to attract, motivate, and retain talent. Changes in executive leadership structure and freezing of the EDCP impact certain employees. The company emphasizes culture and values.
- Patients: The strategic focus on home-based care aims to ensure patients receive necessary care, manage health independently, and improve outcomes.
- Providers and Insurers: Accendra Health aims to be a leading partner in care, connecting patients, providers, and insurers for better healthcare.
- Communities: Accendra Health Foundation supports charitable and civic organizations, focusing on Healthcare, Environment, and Community, with significant contributions and employee volunteerism.
- Creditors: Total debt increased by $209 million, though net debt was reduced by $46 million, which could be a mixed signal for creditors.
Next Steps
- Shareholders to vote on director nominees, auditor ratification, executive compensation, and the Amended and Restated 2023 Omnibus Incentive Plan at the Annual Meeting on May 14, 2026.
- The Board and management will review significant accomplishments, future opportunities, and initiatives at the Annual Meeting.
- The OP&C Committee will evaluate compensation and governance practices to align with the transformed company and prevailing market dynamics.
- The company expects the shares available under the Amended and Restated 2023 Plan to be sufficient for anticipated awards for the next year if approved.
- The Audit Committee will determine if any shares have been earned for 2024 PSUs following completion of 2026.
- The Audit Committee will determine if any shares have been earned for 2025 PSUs following completion of 2027.
Key Dates
| Date | Description |
|---|---|
| 2019 | Mark A. Beck and Edward A. Pesicka became directors. |
| 2020 | Gwendolyn M. Bingham became a director. |
| 2021-01-01 | Start of fiscal year for which certain equity awards were granted and performance measured. |
| 2021-12-31 | End of fiscal year for which certain equity awards were granted and performance measured. |
| 2022 | Kenneth Gardner-Smith and Teresa L. Kline became directors. |
| 2022-01-01 | Start of fiscal year for which certain equity awards were granted and performance measured. |
| 2022-12-31 | End of fiscal year for which certain equity awards were granted and performance measured. |
| 2023-01-01 | Start of three-year performance period for 2023 PSUs (cumulative adjusted EPS). |
| 2023-03-01 | Vesting commencement date for certain RSUs and PSUs granted in 2023. |
| 2023-05-11 | Effective date of the 2023 Omnibus Incentive Plan. |
| 2023-05-17 | Vesting commencement date for certain RSUs granted to Heath H. Galloway. |
| 2023-12-31 | End of fiscal year for which certain equity awards were granted and performance measured; end of three-year performance period for 2023 PSUs, resulting in forfeiture. |
| 2024-01-01 | Start of three-year performance period for 2024 PSUs (adjusted EPS and relative TSR). |
| 2024-03-01 | Vesting commencement date for certain RSUs and PSUs granted in 2024. |
| 2024-07-01 | Grant date for one-time RSUs to Jonathan A. Leon for Interim CFO responsibilities. |
| 2024-09-23 | Grant date and vesting commencement date for one-time RSUs to Jonathan A. Leon upon promotion to EVP & CFO. |
| 2024-12-05 | Perry A. Bernocchi transitioned to Executive Vice President and Chief Operating Officer. |
| 2024-12-31 | End of fiscal year for which certain equity awards were granted and performance measured. |
| 2025-01-01 | Start of two-year cumulative adjusted EBITDA and three-year relative TSR performance period for 2025 PSUs; Executive Deferred Compensation and Retirement Plan (EDCP) frozen. |
| 2025-02-27 | Board approved amendment and restatement of Officer Severance Policy and Executive Change of Control Severance Agreements. |
| 2025-03-03 | Grant date for annual equity awards (RSUs and PSUs) to NEOs. |
| 2025-05-15 | Effective date for director fee schedule changes; grant date for restricted stock units to directors. |
| 2025-05-21 | OP&C Committee engaged Frederic W. Cook & Co., Inc. (FW Cook) as independent compensation consultants. |
| 2025-06-05 | Cash payment of $80 million to Rotech for termination of acquisition. |
| 2025-12-31 | Finalization of the sale of the Products & Healthcare Services (P&HS) business to Platinum Equity; end of fiscal year 2025; Mr. Long ceased employment with the Company. |
| 2026-01-01 | Mr. Long left the Company; Mr. Galloway assumed oversight of human resources. |
| 2026-03-18 | Record Date for shareholders entitled to vote at the Annual Meeting. |
| 2026-04-02 | Date of the Notice of 2026 Annual Meeting of Shareholders and Proxy Statement availability/mailing. |
| 2026-05-14 | Date of the 2026 Annual Meeting of Shareholders. |
| 2026-05-15 | Vesting date for restricted stock units granted to directors on May 15, 2025. |
| 2026-12-02 | Deadline for shareholder proposals under Rule 14a-8 for the 2027 Annual Meeting. |
| 2026-12-31 | End of fiscal year 2026; end of two-year cumulative adjusted EBITDA performance period for 2025 PSUs; end of three-year adjusted EPS performance period for 2024 PSUs. |
| 2027-03-15 | Deadline for shareholders to provide notice for director nominees under universal proxy rules for the 2027 Annual Meeting. |
| 2027-06-21 | Vesting date for one-time RSUs granted to Jonathan A. Leon on July 1, 2024. |
| 2027-12-31 | End of three-year relative TSR performance period for 2025 PSUs. |
| 2033-05-11 | Termination date of the Amended and Restated 2023 Omnibus Incentive Plan (if not approved, the Prior 2023 Plan terminates on this date). |
Recommendation
holdThe strategic transformation to a pure-play home-based care business is a positive long-term move, aligning with strong industry trends. However, the significant financial underperformance in 2025, including missed targets for the annual incentive plan and forfeiture of prior equity awards, indicates near-term operational challenges. The increased total debt and the terminated Rotech acquisition also present headwinds. While the long-term vision is compelling, the company needs to demonstrate consistent execution and improved financial results in its new focused structure before a more bullish stance can be justified. A 'hold' recommendation allows investors to observe the execution of the new strategy and the realization of its benefits.
Keywords
Accendra Health, Home Healthcare, Medical Equipment, SEC Filing, Proxy Statement, Corporate Governance, Executive Compensation, Strategic Transformation, Patient Direct, Apria, Byram Healthcare, Shareholder Meeting, Equity Incentive Plan, Risk Management, Sustainability, Cybersecurity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.